Dr Christina Davies
Senior Research Fellow, CTSU
- MRC, Senior Research Fellow
Christina Davies studied medicine at the University of Manchester, graduating in 1990 (MB ChB) and in the process, also obtaining an intercalated degree in medical biochemistry (BSc). She subsequently moved into medical research, working at the Medical Research Council’s headquarters where she was involved in developing and managing the Council’s clinical trials and public health research strategies. Whilst at the MRC, she obtained a diploma in health economics before being seconded to the MRC’s CTSU in Oxford in 1995. After moving permanently to CTSU in 1997, she obtained a Masters degree in epidemiology from the London School of Hygiene and Tropical Medicine (1998), whilst continuing her work at CTSU, which has focused primarily on the treatment of early breast cancer. She is now responsible for the overall coordination and scientific direction of the continuing international ATLAS study of tamoxifen in breast cancer, and is involved in the continuing meta-analyses of all the trials in the world of systemic treatments for early breast cancer, which is a major part of the CTSU-based Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None. et al, (2018), The Lancet Oncology, 19, 27 - 39
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan H. et al, (2017), New England Journal of Medicine, 377, 1836 - 1846
10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS.
Davies C. et al, (2017), Lancet, 389, 1884 - 1884
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None. et al, (2015), Lancet, 386, 1341 - 1352
Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).
Forbes JF. et al, (2014), JOURNAL OF CLINICAL ONCOLOGY, 32